How to use these tools
The two calculators above are planning aids. They exist so that the numbers you meet during an online assessment, your body mass index and the kind of change a course of treatment is measured in, mean something to you before you start. They are not eligibility checks and they do not decide anything.
The decision belongs to a licensed healthcare provider, who for applicable Bodi Envi programs practises through Wasef Health, PC. The provider reads your whole assessment, including your health history and your medications, and determines whether treatment is appropriate for you. Treatment is not guaranteed, and a number from a calculator does not change that in either direction. Use the tools to understand, then use the assessment to ask.
What BMI is and how it is calculated
Body mass index is a single number that relates your weight to your height. The CDC defines it as a person’s weight in kilograms divided by the square of their height in meters. The calculator above accepts feet, inches and pounds, and converts them with the standard imperial factor: 703 times weight in pounds, divided by height in inches squared.
The CDC publishes the adult categories the calculator shows. Below 18.5 is underweight. From 18.5 to less than 25 is healthy weight. From 25 to less than 30 is overweight. From 30 upward is obesity, which the CDC divides into class 1 from 30 to less than 35, class 2 from 35 to less than 40, and class 3, which it also calls severe obesity, at 40 or greater.
Two things about BMI are worth saying plainly. First, it is a screening measure. It does not measure body fat and it does not know whether a given weight is muscle, bone or fat, so two people with the same BMI can be in very different shape. Second, it is one of the things a provider looks at, not the only one. The large trials of these medications enrolled adults with a BMI of 30 or more, or 27 or more with a weight-related condition, and the FDA-approved products are indicated for adults with obesity or with overweight and a weight-related condition, but a provider’s decision rests on your whole picture.
What the weight change estimate is based on
The estimator takes the weight you enter and shows what a 15 percent change would be, in pounds or kilograms, along with the weight that would leave you at. The percentage is a flat illustration and it was chosen to sit near one published figure: in the STEP 1 trial, published in the New England Journal of Medicine in 2021, adults with obesity or overweight who took branded semaglutide 2.4 mg once weekly for 68 weeks alongside lifestyle support had a mean body weight change of 14.9 percent, against 2.4 percent with placebo.
That is an average from one trial of one branded product, and it is offered here as a way to picture what the research measured, not as a forecast of your result. Participants in that trial varied widely around the mean. The trial studied Wegovy®, not a compounded medication, and personalized compounded semaglutide is not FDA-approved and not equivalent to it. Your own course depends on your dose, how long you stay on treatment, what you eat, how you move and factors nobody can predict. Individual experiences and outcomes vary, and no page on this site promises a number.
The estimator’s percentage is set in the page itself, so the tool and this explanation cannot drift apart. If Bodi Envi changes the illustration, this paragraph changes with it.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the Plans page shows
Once you understand the numbers, the practical questions are what a program costs and what it includes, and those live on the Plans page. Bodi Envi publishes one price per program, the same at every dose: personalized compounded semaglutide from $155 per month billed monthly to $125 per month on a twelve month plan, and personalized compounded tirzepatide from $229 per month to $175 per month on the same terms. Each program includes the online assessment, review by a licensed provider, messaging with your care team, a GLP-1 ebook and diet plan, and the medication when it is prescribed.
Medication is included only when a licensed healthcare provider determines treatment is medically appropriate and issues a prescription, and completing an assessment or paying for a program does not guarantee one. Compounded personalized semaglutide and compounded personalized tirzepatide are not FDA-approved and are not equivalent to FDA-approved products. Brand names are trademarks of their respective owners.